Ovarian Mucinous Adenocarcinoma
NCI Definition: An invasive adenocarcinoma that arises from the ovary and is characterized by the presence of malignant epithelial cells that contain intracytoplasmic mucin. There is cellular atypia, increased layering of cells, complexity of glands, and papillary formations. 
Ovarian mucinous adenocarcinomas most frequently harbor alterations in KRAS, TP53, CDKN2A, CDKN2B, and PIK3CA .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in ovarian mucinous adenocarcinoma .
There is 1 clinical trial for ovarian mucinous adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains ovarian mucinous adenocarcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).
Carboplatin, defactinib, and paclitaxel are the most common interventions in ovarian mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.